Drugs / ACD440
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05416931 | Jun 2022 → Mar 2023 | neuropathy, painful | AlzeCure Pharma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04704232 Comparator | Jan → Mar 2021 | — | AlzeCure Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACD440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04704232 ↗ |
| Route | Topical | “topical administration of ACD440” NCT04704232 ↗ |